New Research from Accenture Reveals Gap in Pharma R&D’s Journey to Delivering Better Patient Outcomes
May 25 2016 - 8:27AM
Business Wire
Adoption of digital transformation to drive
patient outcomes may improve competitive position for pharma
R&D organizations
Despite R&D-focused pharmaceutical executives recognizing
digital as the primary driver to be more patient-outcome focused,
only half of them are currently adopting digital, according to a
new report from Accenture (NYSE:ACN).
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160525005444/en/
Which of the following statements best
describes the degree to which your pharma R&D organization is
adopting new digital technologies? (Photo: Business Wire)
The report - Industry at a Crossroads: The Rise of Digital in
the Outcome-Driven R&D Organization - is based on a survey of
nearly 80 R&D executives at leading pharmaceutical companies in
the United States and Europe.
When asked to identify the areas in which digital technologies
will have the greatest impact on the industry, executives cited
“transforming their R&D model to become more patient-focused”
more often than any other area (29 percent), ahead of “improving
R&D productivity through digitized processes” (22 percent);
“enhancing quality and compliance to meet changing regulatory
requirements” (18 percent); and “cost reduction in R&D to
improve productivity” (12 percent), among other areas.
However, 42 percent of respondents said they are still
“exploring” how digital might improve their organizations, with
another three percent saying they are still “waiting and
seeing” how digital is deployed before developing their own digital
capabilities.
“R&D pharma executives clearly believe that digital can help
them accomplish their goal of improving patient outcomes,” said
Kevin Julian, managing director of Accelerated R&D Services,
Accenture Life Sciences. “Companies that are slow to embrace
digital may run the risk of conceding competitive position, profit
margin and even customer loyalty.”
While all but one (99 percent) of the executives surveyed
said that increasing focus on patient outcomes is a “critical” or
“very important” priority, four in 10 respondents (39 percent) said
that focusing more on patient outcomes was already a key priority
of their R&D organizations, and half (49 percent) said that it
should be the top priority by 2020.
The research also revealed those pharmaceutical companies that
have already adopted digital report significantly stronger R&D
capabilities in key areas. They are far more advanced in core
process redesign of Target Product Profile (TPP) and Clinical
Development Plan (CDP), collaborating with other commercial
organizations, harnessing real-world data analytics, and using
digital to make more effective use of Medical Science Liaisons
(MSLs).
“R&D plays a critical role in deciding which products or
services get developed, and how quickly,” Julian said. “Digital can
help R&D organizations make the right decisions more quickly by
improving data integration and analysis, as well as through better
collaboration with and engagement of patients, providers,
regulators and other stakeholders.”
In the report, Accenture suggests that, to capture the benefits
of digital technologies, R&D pharmaceutical leaders should
consider the following steps:
- Outline a digital strategy that aligns
with current company and R&D priorities. As an example, for
each strategic goal, identify digital enablers that reflect the
same scope, objective, competitive differentiation, and patient
value.
- Map specific digital enablers to major
clinical processes as well as to important stakeholders, such as
investigators, patients, caregivers and vendors. Then, define
quantifiable value, ideal outcomes and experiences for
investigators, patients, caregivers, and vendors.
- Think ‘out of the box’ to gain market
growth in specific therapeutic areas, such as lifestyle diseases or
most chronic illnesses, as well as customer segments, like
non-mobile patients. For instance, therapeutic areas such as
lifestyle diseases or most chronic illnesses, as well as customer
segments like non-mobile patients, can provide the best opportunity
to think broadly and differently about the strategy to engage
patients to ensure improved outcomes.
- Enable stronger collaboration with
other digital adoption stakeholders, such as the internal
commercial organization as well as third parties.
- Foster a more digital culture and
mindset by investing in or leveraging existing digital capabilities
in R&D. This could range from data analytic skills and working
with Real World Evidence platforms to social media engagement.
Click here to learn more about Accenture Life Sciences latest
research: Industry at a Crossroads: The Rise of Digital in the
Outcome-Driven R&D Organization.
About the ResearchMcGuire Research conducted an email
survey of 76 R&D executives at leading pharmaceutical companies
in November 2015. The executives represented 35 US-based companies
and 41 companies based in France, Germany, Switzerland and the
United Kingdom. All respondents were focused on R&D as their
primary role within a pharmaceutical company, with 86 percent
serving as their organization’s most-senior R&D executive or
senior divisional R&D executive, and the remainder (14 percent)
serving as a senior R&D technology executive. Twenty-nine
respondents (38 percent) are from pharmaceutical companies
with revenues of at least US$11 billion, and 47 respondents
(62 percent) are from pharmaceutical companies with revenues
between US$1 billion and US$10 billion.
About AccentureAccenture is a leading global professional
services company, providing a broad range of services and solutions
in strategy, consulting, digital, technology and operations.
Combining unmatched experience and specialized skills across more
than 40 industries and all business functions – underpinned by the
world’s largest delivery network – Accenture works at the
intersection of business and technology to help clients improve
their performance and create sustainable value for their
stakeholders. With approximately 373,000 people serving clients in
more than 120 countries, Accenture drives innovation to improve the
way the world works and lives. Visit us
at www.accenture.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160525005444/en/
AccentureCam Granstra, + 1
312-693-5992cameria.l.granstra@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Apr 2023 to Apr 2024